查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862519

近距離放射治療市場：按劑量率、最終用戶、產品、治療類型和應用分類 - 全球預測（2025-2032 年）

Brachytherapy Market by Dose Rate, End User, Product, Treatment Type, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，近距離放射治療市場規模將達到 16.1 億美元，複合年成長率為 5.99%。

關鍵市場統計數據
基準年 2024 10.1億美元
預計年份：2025年 10.7億美元
預測年份 2032 16.1億美元
複合年成長率 (%) 5.99%

近距離放射、技術進步以及影響其當前應用和實踐的戰略考慮。

近距離放射已成為現代腫瘤治療的重要組成部分。其核心在於能夠以高生物療效將適形放射治療精準地輸送到特定標靶區，同時保護鄰近正常組織。隨著影像、治療計劃和實施技術的日益成熟，近距離放射技術已從傳統的低劑量率植入發展到多種高精度方法，並整合了3D成像和影像引導的自適應工作流程。本文概述了影響臨床醫生、管理人員和技術開發人員對近距離放射說明的臨床因素、技術促進因素以及相關人員的優先事項。

臨床上，對於某些疾病部位而言，局部控制和器官保留能夠顯著提高患者的生活品質，因此這種治療方法仍然至關重要。技術進步（例如，改進的自動化後荷機、先進的施用器設計和新型放射源選擇）以及先進的影像技術，縮短了手術時間，提高了治療的可重複性，並擴大了適合間質和腔內治療的患者群體。同時，手術場所也更加多樣化，包括專業的門診機構、綜合癌症中心和傳統醫院手術室，改變了治療路徑和資金規劃需求。

從策略角度來看，相關人員必須權衡臨床結果與手術流程效率、資本密集度、培訓需求和監管路徑。在整合放射腫瘤學、醫學物理和外科專業的跨學科團隊中，手術流程是創造價值的核心。本導言概述了當前的臨床原理、正在重塑實踐的技術基礎以及影響採購和實施決策的經濟和營運因素，為深入分析奠定了基礎。

治療平台、影像整合和臨床實踐的融合發展如何從根本上重塑近距離放射治療的治療模式和技術應用

由於設備工程、影像整合和臨床證據完善等方面的整合進步，近距離放射領域正經歷著變革性的轉變。首先，輸送平台的演進強調精準性和操控性。遠端後裝自動化、改進的針頭和施用器幾何形狀以及數位化連接功能正在減少人為操作的差異，並提高手術的可重複性。因此，醫療團隊能夠實施更一致的劑量繪製策略並縮短術中工作流程，進而影響治療路徑和資源分配。

其次，先進影像技術在治療過程中的應用正在重塑標靶區定義和檢驗的方式。能夠實現即時或近即時可視化的成像方式有助於建立更嚴格的安全邊界和自適應治療計劃，使臨床醫生能夠在控制毒性的同時，對抗藥性腫瘤亞區進行劑量強化。同時，小型化感測器和改進的傳輸裝置正在加強放射源管理系統和施用器系統之間的聯繫，減少治療過程中的摩擦，並提高品質保證流程中的數據可追溯性。

第三，隨著證據不斷明確疾病部位與跨技術適應症，臨床實務模式日益完善。成熟的間質和腔內療法正與混合療法和標靶表面治療相結合，從而形成更豐富的治療套件。醫療機構的應對措施也在轉變，效率的提高、更明確的患者選擇標準以及當日出院通訊協定使得某些手術能夠在門診手術中心進行。這些變革性的變化迫使醫療設備製造商、服務供應商和臨床領導者重新思考其產品開發、培訓和實施策略，以適應以精準性、高效率和以患者為中心的顯著療效為優先的醫療保健生態系統。

評估2025年關稅變化及其對近距離放射治療供應鏈、籌資策略、臨床營運和政策參與的實際影響

2025年的政策環境引入了關稅調整，這將對近距離放射治療行業的供應鏈、籌資策略和營運預算產生重大影響。影響醫療設備和放射性材料物流的關稅變化進一步凸顯了建立穩健的採購系統和加強監管合規計畫的重要性。對於依賴複雜跨境供應鏈的機構而言，額外的成本和海關相關的不確定性迫使它們重新評估採購計劃，並與製造商和經銷商密切合作，以避免治療計劃中斷。

在營運層面，關稅促使企業採取多項策略性應變措施。醫療服務提供者和經銷商增加了庫存緩衝，並修訂了合約條款，納入了前置作業時間緊急應變和價格保護條款。製造商正在加快本地化生產，並調整供應鏈網路，以降低關稅波動帶來的風險。這些調整往往需要權衡利弊，雖然在已實施的地區提高了可預測性，但也給資本配置和營運利潤率帶來了壓力。

臨床上，這些上游影響促使人們更加重視耗材使用的標準化和手術流程效率的最佳化。多學科團隊正在審查醫療設備使用通訊協定，並探索在保持臨床療效的同時，減少對單一來源組件依賴的方案。從監管和政策角度來看，這些關稅調整凸顯了行業相關人員和政策制定者之間持續合作的必要性，以確保醫療服務的連續性，並在滿足國內產業目標的同時，兼顧提供高品質、及時腫瘤治療的實際情況。

透過詳細的細分分析，將劑量率、最終用戶、產品配置、治療類型和臨床應用與策略性產品選擇和實施決策聯繫起來。

理解細分市場的細微差別對於解讀整個近距離放射治療流程中的應用模式、產品優先排序以及臨床工作流程的影響至關重要。從劑量率的角度來看，高劑量率 (HDR)、低劑量率 (LDR) 和脈衝劑量率 (PDR) 模式之間的差異對臨床適應症、手術物流和資源規劃具有重要意義。高劑量率系統強調借助先進的後荷機和精確的放射源管理實現短時高強度治療。同時，低劑量率方法仍然是某些適應症的持久解決方案，在這些適應症中，延長治療時間具有臨床優勢。脈衝劑量率方法則介於兩者之間，兼顧了生物學因素和實際工作流程的特徵。

最終使用者的特徵會顯著影響需求模式和採購行為。例如，門診手術中心優先考慮的是能夠簡化人員配置並加快患者周轉的緊湊高效系統，而癌症研究所則重視多學科工作流程、研究能力以及與複雜規劃基礎設施的整合。醫院通常兼顧這兩種需求，需要能夠部署於住院和門診環境並與其整體資本設備策略一致的多功能解決方案。

產品細分決定了設計要求和服務模式。後荷機分為手動和遙控兩種，需要在安全性、自動化和使用者人體工學之間取得平衡。手動系統在資源有限的環境或特定操作流程中仍然適用，而遙控系統則支援自動化方案整合並降低醫護人員的輻射暴露。施放器及其配件（包括施放器、針頭和運輸裝置）的設計必須以最佳化定位精度、病患舒適度和滅菌流程為目標。放射源的選擇，包括銫-137、碘-125、銥-192、鈀-103和釔-90等放射性核種，決定了屏蔽措施、法規遵循和臨床劑量策略。

治療方法（間質治療、腔內治療和表淺治療）的差異決定了手術的複雜性和器械的兼容性。間質治療需要可調節的針頭系統和精確的容積規劃，腔內治療依賴於施放器的幾何形狀和穩定性，而淺表治療則依賴適用於不同解剖部位的可調節施放器和固定機制。此外，乳房、婦科、頭頸部和前列腺等特定應用領域對產品和工作流程提出了不同的要求。乳房治療包括混合療法、MamSite 和 SAVIScout 等技術，每種技術在植入技術和患者選擇方面各有優劣。婦科治療則根據腫瘤擴散程度結合間質治療、腔內治療和表淺治療。同時，頭頸部治療又細分為更具體的區域——喉部、口腔和口咽部——需要在入路、劑量和功能保留之間取得平衡。前列腺治療策略根據植入方式的不同而有所差異，包括永久性植入和植入植入技術，以及在放射源處理、影像追蹤和患者諮詢等方面的操作差異。這些細分維度指南產品藍圖、培訓重點和商業化策略，使相關人員能夠針對不同的臨床情況最佳化最佳方案。

區域對比分析重點闡述了美洲、歐洲、中東和非洲以及亞太地區的趨勢將如何影響臨床應用、報銷和部署策略。

區域趨勢將對近距離近距離放射技術的應用時機、監管路徑和商業模式產生決定性影響。美洲地區擁有多元化的醫療服務體系，涵蓋公立和私人醫療機構，部分地區聚集了許多學術機構，這些機構推動臨床創新和手術流程的改善。報銷機制和機構資本週期影響採購時間表，尤其注重透過結合手術和放射治療的綜合治療路徑來最佳化治療效果。

歐洲、中東和非洲地區（EMEA）的管理體制和醫療基礎設施錯綜複雜。在歐洲部分地區，統一的監管標準和集中化的報銷流程加速了實證技術的應用。同時，中東和北非（MENA）各市場的基礎設施成熟度差異顯著，這為模組化、成本效益高的解決方案和能力建設舉措創造了機會。在全部區域，人才培育、跨國合作以及官民合作關係是指導技術應用策略的常見方向。

亞太地區腫瘤服務的快速現代化、對三級醫療機構的大量投資以及日益重視精準醫療以符合人口健康優先事項的特點，都是其顯著特徵。該地區的規模和多樣性推動了實用、擴充性解決方案的採用，從而能夠在都市區進行大規模部署並覆蓋更廣泛的地域。供應鏈韌性、與當地監管機構的合作以及與區域臨床領導者的夥伴關係是成功進入市場和持續推廣的通用要素。在所有地區，使產品價值提案與當地的醫保報銷體系、醫療服務提供者的能力和醫療服務模式相匹配，對於產生有意義的臨床和商業性影響至關重要。

競爭格局概述顯示，整合平台、專業創新者和以服務主導的模式正在重塑供應商選擇和長期夥伴關係關係。

近距離放射治療領域的競爭動態反映了現有產品系列與專注於特定臨床需求和工作流程最佳化的敏捷創新者之間的平衡。領先的醫療設備製造商正投資於整合系統，這些系統整合了後荷機、施放施用器系統、治療計畫軟體和服務框架，旨在提供全面的解決方案，以解決醫療服務提供者對互通性和生命週期支援的擔憂。這些公司通常強調循證實踐、法規遵從性以及廣泛的培訓計劃，以支持在各種臨床環境中推廣應用。

同時，專業供應商和新興Start-Ups正積極尋求差異化策略，針對特定手術步驟，例如新型施藥器設計、改進的輸送裝置或先進的放射源技術，以縮短手術時間並改善劑量學結果。醫療設備製造商與卓越臨床中心之間的合作正在加速產品檢驗並改善使用者體驗，從而降低機構核准和臨床醫生接受的門檻。服務模式也在不斷發展，包括供應管理協議、耗材訂閱框架和遠端規劃協助，這反映了客戶對可預測營運成本和專業知識的需求。

對於採購人員和臨床領導者而言，供應商的選擇越來越側重於整體擁有成本、培訓和支援、監管記錄以及特定手術獲益的證據。那些能夠展現可靠的上市後監測、健全的品管體係以及積極主動的監管溝通的供應商，更有可能贏得長期的機構合約。在這種競爭激烈的環境中，與最終用戶共同開發解決方案的合作關係，透過將產品功能與日常臨床實踐相結合，能夠創造永續的競爭優勢。

領導者在增強互通性、模組化產品設計、供應鏈韌性以及產生可操作的證據以促進持續採用方面，面臨著切實可行的策略挑戰。

行業領導者應優先考慮切實可行的策略，以使臨床結果與永續的商業模式相契合。首先，應投資於互通性操作系統和開放資料標準，以促進後荷機、規劃軟體、影像設備和醫院資訊系統之間的整合。這將有助於減少實施過程中的阻力，並支持利用即時數據進行品質保證和結果評估的自適應診療路徑。

接下來，我們將開發模組化產品系列，可根據不同終端用戶的需求進行客製化，從面向門診手術中心的簡化解決方案到面向癌症研究機構的綜合平台，從而實現更精準的市場細分。與模組化設計同步，我們將拓展培訓和認證項目，以提升臨床醫生的熟練程度，降低手術操作的差異性，從而支持可預測的患者治療效果。

第三，我們將透過多元化零件採購、建立區域分銷中心以及協商靈活的合約條款（充分考慮關稅和物流方面的不確定性）來增強供應鏈韌性。在採取供應鏈措施的同時，我們將推進積極主動的監管應對計劃，並儘早與相關人員就衛生技術評估進行溝通，以明確區域報銷框架內的價值提案。

最後，我們將推進循證實踐舉措技術創新與可衡量的臨床和經濟終點聯繫起來。務實的多中心註冊研究和有針對性的真實世界研究無需進行長期隨機試驗即可展現比較優勢，從而提供支付方和醫療機構採購方日益需要的數據。透過結合技術互通性、模組化設計、營運彈性以及以證據為導向的策略，行業領導者可以加速負責任地推廣應用，並為患者和醫療保健系統帶來持續價值。

透過透明的三角調查方法，結合關鍵相關利益者訪談、技術文獻回顧和供應鏈分析，獲得嚴謹的洞見。

本分析的調查方法採用三角測量法，結合與關鍵相關利益者的對話、技術文獻的綜合分析以及供應鏈檢驗，以確保可靠的實務證據基礎。主要資料來源包括與臨床醫生、醫學物理學家、採購人員和醫療設備工程師的結構化訪談，以深入了解實際操作流程、實施限制和未滿足的臨床需求。此外，還對同行評審的臨床文獻、醫療設備技術文件和監管指南進行了深入審查，以檢驗臨床性能聲明並闡明安全考慮。

透過供應鏈圖譜繪製和供應商訪談，我們確定了製造地、分銷模式和常見的物流瓶頸，從而獲取營運情報。政策和報銷評估參考了公共指導文件和支付方框架說明，以了解不同醫療保健系統如何評估產品價值。在整個過程中，我們與領域專家進行了多次迭代整合會議，交叉檢驗了我們的發現，以協調不同的觀點並檢驗觀察到的模式。

我們的分析方法採用定性主題編碼來識別反覆出現的挑戰和機遇，並建立了設備能力比較矩陣來突出差異化功能。我們的調查方法強調資訊來源的透明度、分析過程的可重複性，以及與臨床顧問的持續回饋機制，以確保結論是基於實際操作。對於已發表證據有不足之處的情況，我們注記相關專家的意見，以闡明潛在的實踐模式，並明確指出其基本假設的性質。

本文探討如何將臨床效用、技術複雜性和運行彈性結合，以最大限度地發揮近距離放射在現代腫瘤學中的潛力。

總之，近距離放射治療仍然是一項臨床上至關重要的治療方法，它受益於技術的不斷改進、工作流程的最佳化以及針對性證據的累積。此治療方法的優點在於能夠提供局部、高精度的治療，顯著提高器官保留率和患者生活品質，尤其是在整合到局部診療路徑中時。隨著治療系統的自動化程度不斷提高以及影像融合技術的發展，治療流程的效率和可重複性將進一步提升，使其能夠應用於更廣泛的臨床場景。

然而，相關人員必須應對不斷變化的採購趨勢、監管要求以及影響醫療資源取得和營運永續性的供應鏈因素。針對每家機構（無論是門診手術中心、癌症研究所還是醫院）的獨特需求量身定做產品，設計模組化和可互操作系統，並優先考慮可操作的證據生成，這些都是將技術可能性與臨床和組織實際情況相結合的關鍵步驟。最終，該領域的成功將取決於能否將工程創新轉化為持續的臨床效益和精簡的醫療服務，同時維持一個具有韌性和合規性的供應鏈生態系統。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 基於先進影像技術的前列腺癌個人化低劑量率近距離放射治療粒子植入術
  • 引入一種高劑量率遠端裝載系統，該系統整合即時劑量測定功能，用於子宮頸癌治療
  • 開發可生物分解的間隔物以減少周圍正常組織受到的輻射暴露
  • 整合人工智慧驅動的治療計劃軟體以最佳化近距離放射治療中的種子放置和劑量分佈
  • 利用球囊導管系統擴大腔內近距離放射治療在早期乳癌的應用
  • 推出用於複雜婦科及頭頸部近距離放射治療手術的3D列印客製化施用器

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依劑量率分類的近距離放射治療市場

  • 高劑量率
  • 低劑量率
  • 脈衝劑量率

第9章 依最終使用者分類的近距離放射治療市場

  • 門診手術中心
  • 癌症研究所
  • 醫院

第10章 近距離放射治療產品市場

  • 後荷機
    • 手動輸入
    • 遙控類型
  • 塗抹器和配件
    • 應用程式
    • 針
    • 轉移裝置
  • 放射性物質
    • Cs-137
    • I-125
    • Ir-192
    • Pd-103
    • Y-90

第11章 近距離放射治療市場（依治療方法分類）

  • 間質療法
  • 腔內照射
  • 表面輻射

第12章 按應用分類的近距離放射治療市場

  • 胸部
    • 混合
    • 猛獁象遺址
    • SAVIScout
  • 婦科
    • 間質療法
    • 腔內照射
    • 表面輻射
  • 頭部和頸部
    • 喉
    • 口腔
    • 口咽
  • 攝護腺
    • 永久植入式
    • 暫時植入

第13章 區域近距離放射治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的近距離放射治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國近距離放射治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Varian Medical Systems, Inc.
    • Elekta AB（publ）
    • CR Bard, Inc.
    • Eckert & Ziegler AG
    • Ion Beam Applications SA
    • Best Medical International, Inc.
    • IsoRay, Inc.
    • Theragenics Corporation
    • Beijing Atom High Tech Co., Ltd.
    • NTP Radioisotopes SOC Limited
Product Code: MRR-521BAA36EB3B

The Brachytherapy Market is projected to grow by USD 1.61 billion at a CAGR of 5.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.01 billion
Estimated Year [2025] USD 1.07 billion
Forecast Year [2032] USD 1.61 billion
CAGR (%) 5.99%

A succinct yet comprehensive overview of brachytherapy's clinical importance, technological advances, and strategic considerations shaping adoption and delivery today

Brachytherapy occupies a pivotal niche in contemporary oncologic care, anchored by its capacity to deliver conformal radiation with high biological effectiveness to defined targets while sparing adjacent normal tissues. As imaging, treatment planning, and delivery technologies have matured, brachytherapy techniques have expanded from classic low dose rate implants to a diverse suite of high precision approaches that integrate three-dimensional imaging and image-guided adaptive workflows. This introduction synthesizes clinical drivers, technological enablers, and stakeholder priorities that together shape how brachytherapy is evaluated by clinicians, administrators, and technology developers.

Clinically, the modality remains indispensable for specific disease sites where local control and organ preservation yield meaningful quality-of-life advantages. Technological progress such as improved afterloader automation, advanced applicator design, and novel source options have converged with enhanced imaging modalities to reduce procedure times, increase reproducibility, and broaden the patient cohorts amenable to interstitial and intracavitary approaches. In parallel, procedural settings have diversified to include specialized ambulatory environments, integrated oncology centers, and traditional hospital theaters, altering care pathways and capital planning prescriptions.

From a strategic perspective, stakeholders must weigh clinical performance against procedural throughput, capital intensity, training requirements, and regulatory pathways. As multidisciplinary teams integrate radiation oncology, medical physics, and surgical specialties, the procedural workflow becomes a central locus for value creation. This introduction establishes the baseline context for deeper analysis by outlining the contemporary clinical rationale, the technical building blocks redefining practice, and the economic and operational considerations that inform procurement and adoption decisions.

How convergent advances in delivery platforms, imaging integration, and clinical practice are fundamentally reshaping brachytherapy care delivery and technology adoption

The brachytherapy landscape is experiencing transformative shifts driven by convergent advances in device engineering, imaging integration, and clinical evidence refinement. First, the evolution of delivery platforms has emphasized precision and usability; remote afterloading automation, refined needle and applicator geometries, and digital connectivity features are reducing manual variability and enhancing procedural reproducibility. As a result, teams are able to implement more consistent dose painting strategies and shortened intraoperative workflows, which in turn influences care pathways and resource allocation.

Second, the integration of advanced imaging into the treatment chain is reshaping how targets are defined and verified. Modalities that enable real-time or near-real-time visualization support tighter margins and adaptive replanning, thereby allowing clinicians to escalate dose to resistant tumor subvolumes while controlling toxicity. Concurrently, miniaturized sensors and improved transfer devices are enhancing the interface between source management and applicator systems, reducing procedural friction and improving data traceability for quality assurance processes.

Third, clinical practice patterns are becoming more nuanced as evidence clarifies indications across disease sites and techniques. Hybrid approaches and targeted surface treatments are emerging alongside established interstitial and intracavitary therapies, creating a richer procedural toolkit. Institutional pathways are also adapting, with ambulatory surgical centers increasingly able to host select procedures due to improvements in efficiency, patient selection, and same-day discharge protocols. These transformative shifts collectively mandate that device makers, service providers, and clinical leaders rethink product development, training, and deployment strategies to align with a healthcare ecosystem that prizes precision, throughput, and demonstrable patient-centered outcomes.

Assessment of 2025 tariff shifts and their practical implications for brachytherapy supply chains, procurement strategies, clinical operations, and policy engagement

The policy environment in 2025 introduced tariff adjustments that have material implications for supply chains, procurement strategies, and operating budgets across the brachytherapy sector. Tariff changes affecting medical devices and radioactive source logistics have accentuated the importance of resilient sourcing and enhanced regulatory-compliance planning. Organizations that rely on complex cross-border supply chains have found that incremental costs and customs-related uncertainties require revised procurement timelines and closer coordination with manufacturers and distributors to avoid disruption to treatment schedules.

Operationally, the tariffs have prompted several strategic responses. Healthcare providers and distributors have expanded inventory buffering and revisited contractual terms to incorporate lead-time contingencies and price-protection clauses. Manufacturers have accelerated efforts to localize production or adapt supply networks to mitigate exposure to tariff volatility. These adaptations often carry their own trade-offs, creating pressure on capital allocation and operational margins while improving predictability where implemented.

Clinically, the upstream effects translate into an increased emphasis on standardizing consumable use and optimizing procedural efficiency. Multidisciplinary teams are reassessing device utilization protocols and exploring options that maintain clinical outcomes while reducing dependency on single-source components. From a regulatory and policy vantage, these tariff dynamics underscore the need for sustained engagement between industry stakeholders and policymakers to ensure continuity of care and to balance domestic industrial objectives with the practical realities of delivering high-quality, timely oncology services.

Deep segmentation analysis linking dose rate, end user, product architecture, treatment type, and clinical application to strategic product and deployment decisions

A nuanced understanding of segmentation is essential to interpret adoption patterns, product priorities, and clinical workflow implications across the brachytherapy continuum. When viewed through the lens of dose rate, distinctions among High Dose Rate, Low Dose Rate, and Pulse Dose Rate modalities inform clinical indications, procedural logistics, and resource planning. High Dose Rate systems emphasize brief, high-intensity treatments enabled by advanced afterloaders and precise source control, while Low Dose Rate approaches continue to provide durable solutions for specific indications where prolonged exposure profiles are clinically advantageous. Pulse Dose Rate occupies an intermediary role, balancing biological considerations with practical workflow features.

End-user differentiation significantly affects demand characteristics and procurement behavior. Ambulatory Surgical Centers prioritize compact, efficient systems with streamlined staffing and rapid turnover, whereas Cancer Institutes emphasize integration with multidisciplinary workflows, research capabilities, and complex planning infrastructures. Hospitals often straddle both priorities, requiring versatile solutions that can be deployed across inpatient and outpatient settings and that align with broader capital equipment strategies.

Product segmentation drives design imperatives and service models. Afterloaders, divided into manual and remote variants, must balance safety, automation, and user ergonomics; manual systems retain relevance for low-resource contexts and specific procedural preferences, while remote systems support automated planning integration and reduced radiation exposure for staff. Applicator and accessory portfolios-spanning applicators, needles, and transfer devices-require designs that optimize placement accuracy, patient comfort, and sterilization workflows. Source selection, encompassing radionuclides such as Cs-137, I-125, Ir-192, Pd-103, and Y-90, shapes shielding, regulatory handling, and clinical dosing strategies.

Treatment type differentiation among Interstitial, Intracavitary, and Surface approaches dictates procedural complexity and device compatibility. Interstitial treatments demand adaptable needle systems and precise volumetric planning, intracavitary techniques hinge on applicator geometry and stability, and surface modalities rely on conformal applicators and attachment mechanisms suitable for varying anatomical sites. Finally, application-specific considerations across Breast, Gynecological, Head And Neck, and Prostate domains impose distinct product and workflow requirements. Breast applications include technologies such as Hybrid approaches, MammoSite, and SAVIScout, each offering different trade-offs in implantation technique and patient selection. Gynecological practice incorporates interstitial, intracavitary, and surface options to address a spectrum of tumor extents, while head and neck interventions are subdivided into laryngeal, oral, and oropharyngeal niches that demand careful balancing of access, dosimetry, and functional preservation. Prostate strategies differentiate permanent implant techniques from temporary implant approaches, with divergent logistics around source handling, imaging follow-up, and patient counseling. Together, these segmentation axes inform product roadmaps, training priorities, and commercialization tactics as stakeholders optimize offerings for distinct clinical contexts.

Comparative regional intelligence highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics shape clinical adoption, reimbursement, and deployment strategies

Regional dynamics exert a decisive influence on technology adoption timelines, regulatory pathways, and commercial models for brachytherapy. In the Americas, healthcare delivery systems exhibit heterogeneity across private and public providers, with strong pockets of academic centers that drive clinical innovation and procedural refinement. Reimbursement frameworks and institutional capital cycles shape procurement timetables, and there is a notable emphasis on integrated care pathways that combine surgical and radiation modalities to optimize outcomes.

The Europe, Middle East & Africa region presents a complex mosaic of regulatory regimes and healthcare infrastructures. In parts of Europe, harmonized regulatory standards and centralized reimbursement processes can accelerate the diffusion of evidence-backed technologies, while markets in the Middle East and Africa offer divergent levels of infrastructure maturity that create opportunities for modular, cost-conscious solutions and capacity-building initiatives. Across the region, emphasis on workforce training, cross-border collaborations, and public-private partnerships frequently guides implementation strategies.

Asia-Pacific is characterized by rapid modernization of oncology services, substantial investments in tertiary care facilities, and a growing emphasis on precision therapies that align with population health priorities. The region's scale and heterogeneity encourage both large-scale deployments in urban centers and adoption of pragmatic, scalable solutions for broader geographic coverage. Supply chain resilience, local regulatory engagement, and partnerships with regional clinical leaders are common themes that inform successful market entry and sustained adoption. Across all regions, contextualizing product value propositions to local reimbursement, workforce capabilities, and care delivery models remains essential for meaningful clinical and commercial impact.

Competitive landscape overview showing how integrated platforms, focused innovators, and service-driven models are reshaping supplier selection and long-term partnerships

Competitive dynamics in brachytherapy reflect a balance between established players with broad product portfolios and nimble innovators focusing on niche clinical needs or workflow optimization. Leading device manufacturers invest in integrated systems that combine afterloaders, applicator ecosystems, treatment planning software, and service frameworks to present comprehensive solutions that address institutional concerns about interoperability and lifecycle support. These players typically emphasize evidence generation, regulatory compliance, and extensive training programs to support adoption across diverse care settings.

Simultaneously, specialized vendors and start-up entrants pursue differentiated strategies by targeting specific procedural steps, such as novel applicator designs, improved transfer devices, or advanced source technologies that can reduce procedural time or improve dosimetric outcomes. Partnerships between device manufactures and clinical centers of excellence accelerate product validation and refine user experience, thereby lowering barriers to institutional approval and clinician acceptance. Service models have also evolved to include managed supply agreements, consumable subscription frameworks, and remote planning support, reflecting customer preferences for predictable operating costs and access to specialized expertise.

For purchasers and clinical leaders, supplier selection increasingly weighs total cost of ownership, training and support capabilities, regulatory track record, and evidence of procedure-specific benefits. Vendors that demonstrate reliable post-market surveillance, robust quality management systems, and proactive regulatory engagement are better positioned to win long-term institutional commitments. In this competitive context, collaborative engagements that co-develop solutions with end users create durable advantages by aligning product feature sets with day-to-day clinical realities.

Practical strategic imperatives for leaders to enhance interoperability, modular product design, supply resilience, and pragmatic evidence generation for sustained adoption

Industry leaders should prioritize a set of actionable strategies to align clinical outcomes with sustainable commercial models. First, invest in interoperable systems and open data standards that facilitate integration between afterloaders, planning software, imaging modalities, and hospital information systems. This will reduce implementation friction and support adaptive care pathways that leverage real-time data for quality assurance and outcome measurement.

Second, develop modular product portfolios that can be tailored to different end-user needs-from streamlined solutions for ambulatory surgical centers to comprehensive platforms for cancer institutes-thereby enabling more precise go-to-market segmentation. Alongside modularity, expand training and credentialing programs to accelerate clinician proficiency and to reduce variability in procedural performance, which in turn supports predictable patient outcomes.

Third, strengthen supply chain resilience by diversifying component sourcing, establishing regional distribution hubs, and negotiating flexible contractual terms that account for tariff and logistics uncertainties. Complement supply-chain actions with proactive regulatory planning and early engagement with health technology assessment stakeholders to clarify value propositions within local reimbursement frameworks.

Finally, pursue evidence-generation initiatives that link procedural innovations to measurable clinical and economic endpoints. Pragmatic, multi-center registries and targeted real-world studies can demonstrate comparative advantages without requiring lengthy randomized trials, and they provide the data that payers and institutional buyers increasingly demand. By combining technical interoperability, modular design, operational resilience, and focused evidence strategies, industry leaders can accelerate responsible adoption and deliver sustained value for patients and health systems.

Transparent, triangulated research methodology combining primary stakeholder interviews, technical literature synthesis, and supply chain analysis for rigorous insights

The research methodology underpinning this analysis draws upon a triangulated approach that combines primary stakeholder engagement, technical literature synthesis, and supply chain examination to ensure a robust and actionable evidence base. Primary inputs include structured interviews with clinicians, medical physicists, procurement leaders, and device engineers to capture real-world insights on procedural workflows, deployment constraints, and unmet clinical needs. These conversations are complemented by an in-depth review of peer-reviewed clinical literature, device technical documentation, and regulatory guidance to validate clinical performance claims and to contextualize safety considerations.

Operational intelligence was obtained through supply chain mapping and vendor interviews, which identified manufacturing footprints, distribution models, and common logistics bottlenecks. Policy and reimbursement assessments incorporated public guidance documents and payer framework descriptions to understand how product value is appraised across different healthcare systems. Throughout the process, findings were cross-validated through iterative synthesis sessions with domain experts to reconcile divergent perspectives and to test the plausibility of observed patterns.

Analytical techniques included qualitative thematic coding to identify recurrent challenges and opportunities, as well as comparative device feature matrices to highlight differentiating capabilities. The methodology emphasizes transparency in source attribution, reproducibility of analytical steps, and a continuous feedback loop with clinical advisors to ensure that conclusions remain grounded in operational realities. Where gaps in public evidence existed, targeted expert elicitation was used to clarify probable practice patterns while explicitly noting the nature of the underlying assumptions.

Concluding synthesis on how clinical utility, technological refinement, and operational resilience must align to realize brachytherapy's full potential in modern oncology

In conclusion, brachytherapy continues to be a clinically vital modality benefiting from sustained technological refinement, workflow optimization, and targeted evidence development. The modality's strength lies in its capacity to deliver localized, high-precision therapy with meaningful implications for organ preservation and patient quality of life, particularly when integrated into multidisciplinary care pathways. As delivery systems become more automated and imaging integration advances, the modality's procedural efficiency and reproducibility are likely to improve, making it accessible to a broader range of clinical settings.

Stakeholders must, however, navigate evolving procurement dynamics, regulatory requirements, and supply chain considerations that shape access and operational sustainability. Tailoring product offerings to the distinct needs of ambulatory surgical centers, cancer institutes, and hospitals; designing modular, interoperable systems; and prioritizing pragmatic evidence generation will be essential steps to align technological potential with clinical and institutional realities. Ultimately, success in this space will be measured by the ability to translate engineering innovations into consistent clinical benefit and streamlined care delivery while maintaining a resilient and compliant supply ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Personalized low-dose-rate brachytherapy seed implants for prostate cancer guided by advanced imaging techniques
  • 5.2. Adoption of high-dose-rate remote afterloading systems with integrated real-time dosimetry for cervical cancer treatment
  • 5.3. Development of biodegradable brachytherapy spacers to minimize radiation exposure to surrounding healthy tissues
  • 5.4. Integration of AI-driven treatment planning software to optimize seed placement and dose distribution in brachytherapy
  • 5.5. Expansion of intracavitary brachytherapy applications for early-stage breast cancer using balloon catheter systems
  • 5.6. Emergence of 3D-printed customized applicators for complex gynecological and head and neck brachytherapy procedures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brachytherapy Market, by Dose Rate

  • 8.1. High Dose Rate
  • 8.2. Low Dose Rate
  • 8.3. Pulse Dose Rate

9. Brachytherapy Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Cancer Institutes
  • 9.3. Hospitals

10. Brachytherapy Market, by Product

  • 10.1. Afterloaders
    • 10.1.1. Manual
    • 10.1.2. Remote
  • 10.2. Applicator And Accessory
    • 10.2.1. Applicators
    • 10.2.2. Needles
    • 10.2.3. Transfer Devices
  • 10.3. Sources
    • 10.3.1. Cs-137
    • 10.3.2. I-125
    • 10.3.3. Ir-192
    • 10.3.4. Pd-103
    • 10.3.5. Y-90

11. Brachytherapy Market, by Treatment Type

  • 11.1. Interstitial
  • 11.2. Intracavitary
  • 11.3. Surface

12. Brachytherapy Market, by Application

  • 12.1. Breast
    • 12.1.1. Hybrid
    • 12.1.2. MammoSite
    • 12.1.3. SAVIScout
  • 12.2. Gynecological
    • 12.2.1. Interstitial
    • 12.2.2. Intracavitary
    • 12.2.3. Surface
  • 12.3. Head And Neck
    • 12.3.1. Laryngeal
    • 12.3.2. Oral
    • 12.3.3. Oropharyngeal
  • 12.4. Prostate
    • 12.4.1. Permanent Implant
    • 12.4.2. Temporary Implant

13. Brachytherapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brachytherapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brachytherapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Varian Medical Systems, Inc.
    • 16.3.2. Elekta AB (publ)
    • 16.3.3. C.R. Bard, Inc.
    • 16.3.4. Eckert & Ziegler AG
    • 16.3.5. Ion Beam Applications S.A.
    • 16.3.6. Best Medical International, Inc.
    • 16.3.7. IsoRay, Inc.
    • 16.3.8. Theragenics Corporation
    • 16.3.9. Beijing Atom High Tech Co., Ltd.
    • 16.3.10. NTP Radioisotopes SOC Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRACHYTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRACHYTHERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRACHYTHERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRACHYTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRACHYTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRACHYTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRACHYTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRACHYTHERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HIGH DOSE RATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LOW DOSE RATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PULSE DOSE RATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REMOTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRACHYTHERAPY MARKET SIZE, BY NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TRANSFER DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SOURCES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRACHYTHERAPY MARKET SIZE, BY CS-137, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRACHYTHERAPY MARKET SIZE, BY I-125, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRACHYTHERAPY MARKET SIZE, BY IR-192, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PD-103, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRACHYTHERAPY MARKET SIZE, BY Y-90, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRACHYTHERAPY MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRACHYTHERAPY MARKET SIZE, BY MAMMOSITE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SAVISCOUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTERSTITIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRACHYTHERAPY MARKET SIZE, BY INTRACAVITARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRACHYTHERAPY MARKET SIZE, BY SURFACE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRACHYTHERAPY MARKET SIZE, BY LARYNGEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRACHYTHERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRACHYTHERAPY MARKET SIZE, BY OROPHARYNGEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRACHYTHERAPY MARKET SIZE, BY PERMANENT IMPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRACHYTHERAPY MARKET SIZE, BY TEMPORARY IMPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY GYNECOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY HEAD AND NECK, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA BRACHYTHERAPY MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY DOSE RATE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY AFTERLOADERS, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY APPLICATOR AND ACCESSORY, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2018-2024 (USD MILLION)
  • TABLE 344. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY SOURCES, 2025-2032 (USD MILLION)
  • TABLE 345. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 348. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 349. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 350. EUROPE, MIDDLE EAST & AFRICA BRACHYTHERAPY MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION